Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Cancer
NCT06540443Phase 1Recruiting
- Sponsor
- MegaPro Biomedical
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MPB-2043 in head and neck squamous cell carcinoma (HNSCC) (4 cohorts), sponsored by MegaPro Biomedical. Primary endpoint: Sensitivity and Specificity of MPB-2043 Enhanced MRI in Detecting Lymph Node Metastasis. Started Dec 2024; status: recruiting.
02
Drugs
MPB-2043
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06540443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06540443.